NEW YORK (GenomeWeb News) — BioMérieux and ExonHit Therapeutics plan to develop a blood-based prostate-cancer screening test aimed at helping doctors weigh the risks of performing surgery to remove tumors, BioMérieux said yesterday.
 
Under the collaboration, BioMérieux will use ExonHit’s genome expression IP to develop DNA chips that can detect “several dozens of nucleic acid markers” and use them to find cancer markers in blood.
 
Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.